Related Experiment Videos
Fractionation and dose in thoracic radiotherapy
1Marie Curie Research Wing for Oncology, Mount Vernon Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, UK.
Lung Cancer (Amsterdam, Netherlands)
|March 1, 1994
Summary
Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) shows improved outcomes for mediastinal non-small cell lung cancer. This accelerated radiotherapy approach offers better tumor control and survival rates compared to conventional methods.
Area of Science:
- Oncology
- Radiation Oncology
- Thoracic Oncology
Background:
- Radiotherapy for mediastinal non-small cell lung cancer (NSCLC) yields suboptimal results.
- Conventional radiotherapy (60 Gy/6 weeks) offers limited primary tumor control (23%) and poor survival rates (1-year: 35%, 2-year: 12%).
Purpose of the Study:
- To evaluate the efficacy of Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) in treating mediastinal NSCLC.
- To compare CHART with conventional radiotherapy in a randomized controlled trial setting.
Main Methods:
- CHART delivers 36 fractions over 12 consecutive days, combining hyperfractionation and acceleration.
- Pilot studies demonstrated improved outcomes with CHART (40% local tumor control, 1-year survival: 60%, 2-year survival: 40%).
- Ongoing UK randomized trials compare CHART against conventional 60 Gy/6 weeks radiotherapy, with over 300 patients enrolled.
Main Results:
- Pilot data suggest CHART significantly enhances local tumor control and patient survival compared to conventional radiotherapy.
- Randomized trials are actively accruing patients to confirm these promising findings in a larger cohort.
Conclusions:
- CHART represents a promising advancement in radiotherapy for mediastinal NSCLC.
- Accelerated and hyperfractionated schedules warrant further investigation for improved thoracic cancer treatment outcomes.